Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Obesity
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Obesity
    Fatty Liver Disease May Raise Heart Disease Risk in Overweight and Obese Children - (DGNews)
    Device Blocking Stomach Nerve Signals Shows Promise in Obesity - (DGNews)
    Gastric Bypass Surgery Linked to Increased Risk of Kidney Stones - (DGNews)
    TopAbstracts in Obesity 06/24/2008 - (DGNews)
    Valsartan Plus Diuretic Has More Favourable Metabolic Effects Than Diuretic-Based Regimen in Obese, Hypertensive Patients: Presented at ESH - (DGDispatch)

    News archive

     Recent webcasts/CME - Obesity
      A Case of Adolescent Obesity: The Role of Bariatric Surgery
      The Growing Problem of Childhood Obesity
      Obesity Hypoventilation Syndrome
      Effects of Physical Activity and Exercise on Reducing Risk for Cardiovascular Disease and Diabetes, with a Focus on the Obese Patient
      Strategies for Lifestyle Modification in the Prevention of Diabetes and Cardiovascular Disease

      Webcasts/CME archive

       Recent cases - Obesity
        Reconstruction of the Gastric Passage by a Side-To-Side Gastrogastrostomy After Failed Vertical-Banded Gastroplasty: A Case Report
        Perforated Appendicitis Masquerading as Acute Pancreatitis in a Morbidly Obese Patient.
        Giant Serous Cystadenoma Arising from an Accessory Ovary in a Morbidly Obese 11-Year-Old Girl: A Case Report
        Consideration of Polypharmacology in Regards to Effective Weight Reduction: A Patient on Diabetes Medication
        Consideration of Polypharmacology in Relation to Effective Weight Reduction: A Patient on Antipsychotic Medication

        Cases archive
          




        my personal edition > obesity > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Investigative Drug Rimonabant Helps Obese Subjects Lose Weight and Reduce Waist Size: Presented at ESC(CARD)2004

        By Ed Susman

        MUNICH, GERMANY -- August 30, 2004 -- Studies with rimonabant continue to show that the investigative drug -- when combined with a diet and exercise program -- results in reductions in weight and abdominal girth, and a decrease in metabolic syndrome.

        "We are still involved in a number of clinical studies with rimonabant," said Luc Van Gaal, MD, Professor of Medicine, Antwerp University, Antwerp, Belgium. "But I believe the company -- Sanofi-Aventis -- will file for regulatory approval in the first quarter of 2005."

        The Phase III Rimonabant in Obesity – Europe (RIO-Europe) study found that the endocannabinoid type 1 blocker rimonabant in its 20 mg dose was significantly better than placebo in getting patients to stay on programs that help them diet and lose weight.

        "Rimonabant breaks the vicious circle by cutting the desire to eat by inhibiting the endocannabinoid activation by receptors in the brain and in adipose tissue," Dr. Van Gaal said here August 29th at the European Society of Cardiology ESC2004 meeting.

        In the study, doctors assigned 1,507 overweight patients to rimonabant 5 mg or 20 mg or to a control group, who was encouraged to lose weight but did not receive the new treatment. Patients needed to have a body mass index greater than 27 and a co-morbidity such as a dyslipidemia to be eligible for the 2-year study.

        In reporting the results after 1 year of treatment, Dr. Van Gaal said of the 599 individuals on the 20 mg of rimonabant, the average person lost 8.6 kg or about 19 pounds compared to an average of about 3.6 kg for the 305 patients on placebo. The difference reached significance at the p<0.001 level. The 603 patients on the lower dose of rimonabant also lost more weight than placebo patients, about 4.8 kg. That difference was also significant versus placebo at the p=0.038 level.

        Nearly 70% of patients treated with rimonabant 20 mg/day lost more than 5% of their initial body weight, compared to 44.2% of patients in the rimonabant 5 mg/day group and 30.5% in the placebo group. In addition, 39% of patients on rimonabant 20 mg/day lost more than 10% of their initial body weight compared to 15.3% of those on rimonabant 5 mg/day and 12.4% of those on placebo.

        Patients on rimonabant 20 mg/day also had an average decrease in their waist circumference of 8.5 cm or about 3.5 inches that reached statistical significance versus placebo. Those patients lost 5.3 cm or about two inches.

        Dr. Van Gaal said the number of patients diagnosed as having metabolic syndrome at baseline -- 42.2% of those assigned to rimonabant 20 mg-- decreased by more than half to 19.6%. About 39.9% of the placebo patients were diagnosed with metabolic syndrome at baseline. After treatment 31% of these patients still had the condition. The difference in reduction was significant to the p<.001 level, he said.


        [Abstract title: "Hot Line 1: RIO-EUROPE: A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities." Abstract 106]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send